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M. Vega de Ce´niga,* R. Go´mez, L. Estallo, L. Rodrı´guez, M. Baquer and A. BarbaDepartment of Angiology and Vascular Surgery, Hospital de Galdakao, Barrio Labeaga S/N,
48960 Galdakao (Bizkaia), SpainObjective. To study the growth rate and factors influencing progression of small infrarenal abdominal aortic aneurysms
(AAA).
Design. Observational, longitudinal, prospective study.
Patients and methods. We followed patients with AAA !5 cm in diameter in two groups. Group I (AAA 3–3.9 cm,
nZ246) underwent annual ultrasound scans. Group II (AAA 4–4.9 cm, nZ106) underwent 6-monthly CT scans.
Results. We included 352 patients (333 men and 19 women) followed for a mean of 55.2G37.4 months (6.3–199.8). The
mean growth rate was significantly greater in group II (4.72G5.93 vs. 2.07G3.23 mm/year; p!0.0001). Group II had a
greater percentage of patients with rapid aneurysm expansion (O4 mm/year) (36.8 vs. 13.8%; p!0.0001). The classical
cardiovascular risk factors did not influence the AAA growth rate in group I. Chronic limb ischemia was associated with
slower expansion (%4 mm/year) (OR 0.47; CI 95% 0.22–0.99; pZ0.045). Diabetic patients in group II had a significantly
smaller mean AAA growth rate than non-diabetics (1.69G3.51 vs. 5.22G6.11 mm/year; pZ0.032).
Conclusions. The expansion rate of small AAA increases with the AAA size. AAA with a diameter of 3–3.9 cm expand
slowly, and they are very unlikely to require surgical repair in 5 years. Many 4–4.9 cm AAA can be expected to reach a
surgical size in the first 2 years of follow-up. Chronic limb ischemia and diabetes are associated with reduced aneurysm
growth rates.Keywords: Small abdominal aortic aneurysm; Growth rate; Risk factors.Introduction
The prevalence of abdominal aortic aneurysms (AAA)
in the general population is 4–10%.1–3 Small AAA
(!5 cm-diameter) are becoming more common since
the introduction of screening programs in different
countries. Both the UK small aneurysm trial (UKSAT)4
and the aneurysm detection and management trial
(ADAM)5 have shown a very small rupture risk in 4–
5.5 cm aortic aneurysms, and conservative treatment is
currently recommended. However, the widespread
use of endovascular repair of AAA has added some
controversy to the management of 4–5 cm AAA. The
surgical decision is based on the AAA diameter, its
expansion rate, the patient’s age and risk, the
individual center’s surgical morbidity and mortality
and the local experience of endovascular repair.
Predicting the expansion of small AAA and modifyinging author. Dr M. Vega de Ce´niga, Department of
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ment. Female gender, smoking, hypertension, diabetes
mellitus (DM) and peripheral artery disease (PAD)
have been reported to influence aneurysm growth in a
few published papers, with some conflicting results.6–15
The objective of our study was to establish the
growth rate of a large series of !5 cm aortic
aneurysms. We have also analysed which factors
influence the expansion rate.Patients and Methods
This is an observational, prospective study, ran from
January 1988 until August 2004. We followed 352
consecutive patients diagnosed with a small asympto-
matic infrarenal AAA. We used the definition of AAA
established by McGregor (R30 mm).3,17,18 We defined
an AAA as small when its initial diameter was 3–
4.9 cm. In this report we include all the patients with
!5 cm-infrarenal AAA in which we had at least 2
consecutive scans. Our exclusion criteria included:Eur J Vasc Endovasc Surg 31, 231–236 (2006)
doi:10.1016/j.ejvs.2005.10.007, available online at http://www.sciencedirect.com onved.
M. Vega de Ce´niga et al.232R5 cm AAA diameter; location of the AAA other than
infrarenal (juxtarenal, suprarenal, thoracoabdominal
aneurysms); follow-up !2 scans; symptomatic
aneurysms.
We registered demographic data, clinical character-
istics, cardiovascular risk factors (tobacco use, hyper-
tension, diabetes mellitus and hypercholesterolemia),
and other comorbidities which could influence the
aneurysm growth including chronic obstructive pul-
monary disease (COPD), coronary artery disease
(CAD), cerebrovascular disease, peripheral artery
disease (PAD), chronic renal failure, or cancer.
We only included active smokers in the category of
‘tobacco use’. Patients were regarded as hypertensive
when they were being treated (diet or medication) or
their blood pressure was registered above 140/90
twice in basal conditions. We included complete blood
tests in the study of all our patients. Diabetes mellitus
was defined if the blood glucose was R126 mg/dl or if
the patient was being treated by an endocrinologist
(diet, oral hypoglucemiants, insulin). Hypercholester-
olemia was defined as total basal cholesterol levels
R200 mg/dl, LDL levels R100 mg/dl or the
patients were receiving specific medication or a
supervised diet.
COPD was diagnosed when maximal voluntary
ventilation (MVV) was !80% or the patients were
already under treatment. Chronic renal failure was
defined as serum creatinine R1.5 mg/dl. Peripheral
artery disease was diagnosed when the patient
complained of ischemic symptoms and had an ankle-
brachial index (ABI) !0.90. We routinely performed a
carotid duplex-scan on all the patients. We considered
that cerebrovascular disease was present when we
detected an asymptomatic significant (O50%) carotid
stenosis or the patient had a positive history of TIA,
minor or major stroke.
We classified the patients according to the AAA
size: 3–3.9 cm (group I); 4–4.9 cm (group II). Patients
diagnosed with a !4 cm-AAA were followed
annually with an abdominal ultrasound (SONOLINE
SL-2, SIEMENS) utilizing a 3.5 MHz probe. Aneur-
ysms in group II were followed with an abdomino-
pelvic contrast CT-scan every 6 months. We measured
the greatest transverse and antero-posterior outer
diameters of the infrarenal abdominal aorta. All the
scans were performed in the Department of Radiology
of our center.
We registered the serial AAA diameters in each
patient. We calculated the mean aneurysm growth by
dividing the total growth (mm) throughout the follow-
up by the number of years of follow-up for every
patient. We expressed the mean growthGstandard
deviations (SD) in each group. We considered rapidEur J Vasc Endovasc Surg Vol 31, 3 2006growth when the AAA diameter increased
O4 mm/year, because this expansion rate has been
related to the likelihood of eventual operative repair of
small AAA.11 We also registered the number and
percentage of patients in each group whose AAA
reached 5 cm, and we calculated the mean number of
months it took to reach this surgical size.
All the patients were followed until surgery or
death. The aneurysms were repaired when they
reached a 5 cm-diameter or if they expanded
O1 cm/year or they became symptomatic. None of
the aneurysms included in this series was repaired
with endovascular techniques because the endovas-
cular program was introduced in our center in June
2004. No patients were lost to follow-up.
We performed a descriptive statistical analysis,
using the meanGSD for quantitative variables and
the number and percentage of patients for nominal
variables. The expansion rates follow a normal
distribution, as assessed by the Kolmogorov–Smirnov
statistical test (p!0.0001). Averages were compared
with the independent-samples t-test, and proportions
were compared with the Chi-square test. We also used
life tables, Kaplan–Meier and univariant Cox
regression. The patient information was introduced
into a FileMaker Pro 6 data base and the statistical
analysis was performed using the SPSS 10.0 software
(www.spss.com). We accepted p!0.05 as significant.Results
We included 352 patients in the study, 333 (94.6%) men
and 19 (5.4%) women, with a mean age of 71 years (40–
89). The mean initial AAA size was 36.2G5.61 mm
(30–49). The mean follow-up period was 55.2G37.4
months (6.3–199.8). During the follow-up 87 patients
(24.7%) died, 1 (0.3%) of them because of a ruptured
aneurysm, 1 (0.3%) during AAA elective repair. One
patient in group I required an urgent surgical
procedure because of a 3 cm ruptured iliac aneurysm
when the AAA measured 3.7 cm. Two aneurysms
ruptured in group II: one of them at a size of 5.6 cm in a
patient who was considered unfit for elective surgery
due to severe coronary artery disease, the other one at
a size of 6 cm in a patient who had not complied with
the follow-up protocol. The survival rates were 98.5%
at 1 year, 90.6% at 2 years, 80.1% at 5 years and 52.8% at
10 years. The mean expansion rate for the overall
group was 2.87G4.39 mm/year.
Group I consisted of 246 patients with AAA sized
3–3.9 cm, and group II 106 patients with 4–4.9 cm-
AAA. The cardiovascular risk factors and comorbid-
ities of each group are shown in Table 1. The mean
  
 
Fig. 1. AAA growth rates in groups I and II in the first 5 years
of follow-up (statistical analysis: t-test).
Growth Rate of Small AAA 233growth rate was significantly greater in group II
(4.72G5.93 vs. 2.07G3.23 mm/year; p!0.0001; t-test)
(Fig. 1). Group II also had a greater percentage of AAA
with rapid expansion (O4 mm/year) (36.8% vs. 13.8%;
odds ratio-OR 3.63; CI 95% 2.12–6.3; p!0.0001; Chi-
square). Rapid expansion was significantly associated
with reaching a 5 cm-size and undergoing surgical
repair in groups I and II (p!0.0001 for both; Chi-
square). No expansion (0 mm) was observed in 25.2%
of the AAA in group I and 17.9% in group II (pZ0.14;
Chi-square). Thirty-six (14.6%) aneurysms reached
5 cm in group I, and 72 (67.9%) in group II (OR
12.35; CI 95% 7.19–21.28; p!0.0001; Chi-square). The
freedom from expansion to R5 cm were 100 and 74.4%
after 1 year; 97.6 and 44.2% after 2 years; 82.4 and
18.4% after 5 years, respectively, for groups I and II
(Fig. 2). The likelihood of the aneurysm reaching
R5 cm was 11 times greater in group II than in group I
(OR 11.09; CI 95% 7.29–16.89; p!0.0001; univariant
Cox regression). The time it took for the AAA to reach
a surgical size was significantly shorter in group II
(22.4G19.6 vs. 49.7G21.6 months; p!0.0001; t-test).
We observed a greater expansion in bigger AAA
within group I (Table 2). We analysed the influence of
the cardiovascular risk factors and comorbidities on
the AAA growth rate in each group (Tables 3 and 4).
Both gender and the classical risk factors (smoking,
hypertension, DM, hypercholesterolemia) had no
influence on AAA growth in group I. PAD was
associated with a smaller growth rate (%4 mm/year)
(35.3 vs. 53.8%; OR 0.47; CI 95% 0.22–0.99; pZ0.045;
Chi-square). Patients with chronic renal failure had aTable 1. Cardiovascular risk factors and comorbidities in groups I
and II (statistical analysis: t-test, Chi-square)
Group I
(nZ246)
Group II
(nZ106)
OR (95% CI) p
Age (years) 70G8.7
(40–89)
73G7.6
(53–89)
– 0.001
Gender (M/F) 235
(95.5%)/11
(4.5%)
98 (92.5%)/
8 (7.5%)
1.74 (0.68–4.47) 0.24
Tobacco use 83 (33.7%) 30 (28.3%) 1.29 (0.78–2.12) 0.32
HT 123 (50%) 60 (56.6%) 0.77 (0.48–1.21) 0.26
Diabetes
mellitus
43 (17.5%) 15 (14.2%) 1.29 (0.68–2.43) 0.44
Hypercho-
lesterolemia
61 (24.8%) 32 (30.2%) 0.77 (0.48–1.21) 0.29
CAD 94 (38.2%) 49 (46.2%) 0.72 (0.45–1.14) 0.16
COPD 69 (28%) 45 (42.5%) 0.53 (0.33–0.85) 0.008
CRF 39 (15.9%) 21 (19.8%) 0.76 (0.42–1.37) 0.37
PAD 126 (51.2%) 36 (34%) 2.04 (1.27–3.28) 0.003
Carotid artery
disease
45 (18.3%) 20 (18.9%) 0.96 (0.54–1.73) 0.9
Neoplasia 49 (19.4%) 29 (27.4%) 0.66 (0.39–1.12) 0.12
n, number; OR, odds ratio; CI, confidence interval; M/F, male/female;
HT, arterial hypertension; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; CRF, chronic renal failure; PAD,
peripheral artery disease.higher AAA growth rate and more rapid expansion
(O4 mm/year) (29.4 vs. 13.7%; OR 2.63; CI 95% 1.14–
6.06; pZ0.02; Chi-square) (Table 3).
AAA within group II had similar growth rates
irrespective of their initial sizes (Table 2). Diabetic 
  
 
 
Fig. 2. Life-table analysis of the AAA which have remained
small (!5 cm) in groups I and II (statistical analysis:
univariate Cox regression).
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Table 2. AAA expansion variables within groups I and II
(statistical analysis: t-test, Chi-square)
Group I
(nZ246)
3–3.4 cm
(nZ155)
3.5–3.9 cm
(nZ91)
OR
(95% CI)
p
AAA growth
rate
(mm/year)
1.65G2.41 2.8G4.19 – 0.007
Expansion O
4 mm/year
17
(11%)
17
(18.7%)
0.54
(0.26–1.11)
0.091
No expansion
(0 mm)
48
(31%)
14
(15.4%)
2.47
(1.27–4.79)
0.007
AAA reach
5 cm
14
(9%)
22
(24.2%)
0.31
(0.15–0.65)
0.001
Group II
(nZ106)
4–4.4 cm
(nZ62)
4.5–4.9 cm
(nZ44)
P
AAA growth
rate
(mm/year)
4.5G5.38 5.02G6.69 – 0.66
Expansion O
4 mm/year
24
(38.7%)
15
(34.1%)
1.22
(0.55–2.73)
0.63
No expansion
(0 mm)
9
(14.5%)
10
(22.7%)
0.58
(0.21–1.57)
0.28
AAA reach
5 cm
39
(62.9%)
33
(75%)
0.57
(0.24–1.33)
0.19
n, number; OR, odds ratio; CI, confidence interval; AAA, abdominal
aortic aneurysm.
Table 4. Analysis of AAA growth rate (mm/year) according to
gender, cardiovascular risk factors and comorbidities in group II
(nZ106) (statistical analysis: t-test)
Male Female p
Gender 4.92G6.07 2.19G2.99 0.21
Yes No p
Tobacco use 4.42G5.56 4.84G6.1 0.75
HT 5.24G7 4.03G4.12 0.30
Diabetes mellitus 1.69G3.51 5.22G6.11 0.032
Hypercholesterolemia 3.64G5.32 5.18G6.16 0.22
CAD 5.02G6.27 4.46G5.67 0.63
COPD 4.57G6.32 4.82G5.68 0.83
CRF 4.34G4.77 6.24G9.28 0.19
PAD 4.34G6.5 4.91G5.66 0.64
Carotid artery disease 3.22G5.67 5.07G5.97 0.21
Neoplasia 5.1G5.56 4.57G6.1 0.69
HT, arterial hypertension; CAD, coronary artery disease; COPD,
chronic obstructive pulmonary disease; CRF, chronic renal failure;
PAD, peripheral artery disease.
M. Vega de Ce´niga et al.234patients in this group experienced a significantly
lower mean AAA growth rate than non-diabetics
(pZ0.032; t-test). No other cardiovascular risk factor or
comorbidity influenced AAA expansion (Table 4).Discussion
We have analysed the outcome and expansion rates of
a large series of !5 cm AAA. Ultrasound scanning is
the method routinely used for the diagnosis and
follow-up of small AAA, it is simple, safe, reliable,Table 3. Analysis of AAA growth rate (mm/year) according to
gender, cardiovascular risk factors and comorbidities in group I
(nZ246) (statistical analysis: t-test)
Male Female p
Gender 2.07G3.25 2.08G2.74 0.99
Yes No p
Tobacco use 1.87G2.03 2.18G3.69 0.47
HT 2.07G2.68 2.08G3.7 0.99
Diabetes
mellitus
1.72G2.34 2.15G3.38 0.42
Hypercholes-
terolemia
2.15G2.54 2.05G3.43 0.84
CAD 2.09G2.47 2.06G3.62 0.95
COPD 2.01G2.35 2.1G3.51 0.85
CRF 3.63G6.16 1.78G2.2 0.001
PAD 1.69G2.35 2.48G3.91 0.053
Carotid artery
disease
1.87G2.46 2.12G3.38 0.64
Neoplasia 2.4G5.22 1.99G2.51 0.43
HT, arterial hypertension; CAD, coronary artery disease; COPD,
chronic obstructive pulmonary disease; CRF, chronic renal failure;
PAD, peripheral artery disease.
Eur J Vasc Endovasc Surg Vol 31, 3 2006inexpensive and readily accesible. However, the
measurement of infrarenal aortic diameter by ultra-
sound can differ G2 mm compared to CT.16 AAA of
!4 cm-diameter are associated with a negligible risk
of rupture. CT measurements are appropriate for
follow-up of faster growing 4–4.9 cm AAA, which are
very likely to reach a surgical size in the short-term.
The behaviour of AAA strongly depends on the
AAA diameter.6,10,12,15,17,18 AAA 3–3.9 cm expand
slowly, with a mean growth rate of 2.07 mm/year,
and none has ruptured throughout the follow-up. Over
25% did not expand at all over a mean follow-up of 3.5
years. Some series have reported expansion rates of
1.1–7 mm/year with 11.4–34% absence of AAA
growth.6,10–14,17–25 The UK SAT estimated 3–3.9 cm-
AAA rupture risk to be 0.9 per 100 person-years.4,6
These are often young patients with high long-term
survival rates who can be safely managed conserva-
tively. Less than 20% of the patients will need a surgical
repair of their AAA in the first 5 years of follow-up. The
finding that larger AAA within this group (3.5–3.9 cm)
show a greater growth rate than smaller ones
(3–3.4 cm) (2.8 vs. 1.65 mm/year) has also been
reported by other authors (1.5–4.1 vs. 0.9–3.3 mm/
year),11,18 but Solberg recently reported a similar
growth rate in both subgroups (1.75 vs. 1.8 mm/
year).7 AAA smaller than 3.5 cm are stable, !10%
reached 5 cm during the whole follow-up period.
Larger 3.5–3.9 cm-AAA are more important and in
our series 24.2% reached a surgical size. Santilli
reported similar results with 0 and 27% AAA reaching
5 cm, respectively.11
AAA of 4–4.9 cm-diameter expanded twice as
fast in our series. Other authors have reported
similar results, with mean growth rates of
3–6.9 mm/year.10,14,17–20,22–25 The risk of rupture of
Growth Rate of Small AAA 235these AAA has been estimated to be 0.6–2.1% per
year.5,17,26 In contrast to our series, Solberg found an
increased growth rate in the larger AAA in this group
(4.5–4.9 vs. 4–4.4 cm: 3.36 vs. 2.31 mm/year).7
Two thirds of the AAA reached 5 cm in a mean time
of 2 years. Brown calculated that patients with 4.5–
4.9 cm-AAA were 6.8 times more likely to require
surgical repair than those with 3–3.4 cm at entry;
52% of their 4.5–4.9 cm-AAA underwent surgery with
a mean follow-up of 2.2 years.10 In the ADAM study
27% of 4–5.5 cm-AAA randomized to the surveillance
group had undergone surgical exclusion at 2 years’
follow-up, and over 60% at 5 years.5 Young age and
larger AAA size at the initial evaluation increased the
likelihood of surgical repair during the follow-up.15
AAA of 4.5–4.9 cm-diameter expand quite rapidly and
are expected to reach a surgical size in 2–3 years. So,
patients should be evaluated and surgical treatment
could be offered to fit patients, considering of course
every case individually. It is safe to follow AAA
!4.5 cm-AAA.
We routinely perform an abdominal ultrasound
scan in all our patients with PAD as part of their
vascular evaluation, and we have found a high
incidence of AAA in these patients (13%), most of
them (70.9%) !4 cm in size.27 This explains why there
is a significantly higher percentage of PAD in patients
with 3–3.9 cm AAA. PAD has proved to be a protective
factor against rapid expansion in our series. Its effect
on AAA expansion rates shows a very strong trend
(pZ0.053), which can virtually be considered signifi-
cant. And its influence on the rate of rapid expansion is
statistically significant (pZ0.045), which reinforces the
validity of the association. It was also associated with
slower AAA expansion in the UK SAT, with growth
rates reducing by 0.2 mm/year for each fall of 0.2 in
ABI.6 In contrast, chronic renal failure has been
associated with a mean growth rate twice that of
patients with normal renal function. Chang and
Englund found a correlation between older age, recent
stroke and cardiac disease with rapid AAA
growth,13,14 results which have not been confirmed
in our series. Beta-adrenergic blockade has also been
correlated with slower AAA growth.14 Some authors
have reported an association between hypertension
and greater expansion rates8,11,15 while others have not
confirmed this point.6,9,14 Smoking has also been
associated with higher expansion rates of small AAA
in most but not all series.6,9,12–14 We only considered
current smokers in our analysis because we believe
only active smoking can have an effect on the disease.
Other series have included both current and previous
smokers, with a global prevalence of over 90%. The
prevalence of both previous and current smokers inour series was 80.1% (nZ282) and we are fairly
successful in achieving smoking cessation. All this
might help explain the difference in our results on the
impact of smoking compared to other series. Hyperch-
olesterolemia seems to play a minor role in the
pathogenesis and expansion of small AAA.6,9,12,13 A
slower AAA growth rate has been observed in diabetic
patients, with a crude reduction of over 30%.6,11 This
may be explained by the modification of collagens and
decreased synthesis and activity of metalloproteinases
induced by diabetes.28 In our series, only diabetes was
significantly associated with slower expansion in
4–4.9 cm-AAA.
The data reported in this and other published series
can provide a useful guideline of the likelihood of
growth of small AAA, and it can be of value in making
operative decisions on individual patients. Our series
confirms the fact that the expansion rate of small AAA
increases with the AAA diameter. Our follow-up
protocol, which is widely used in several countries,
is safe. AAA smaller than 4 cm expand slowly, they are
very unlikely to require a surgical repair in 5 years.
However, many 4–4.9 cm AAA can be expected to
reach a surgical size in the first 2 years of follow-up, so
the patients can be conveniently prepared for elective
repair. Some patients with specific risk factors, like
chronic renal failure or 4.5–4.9 cm AAA size, should be
monitored closely to determine the appropriate time
for aneurysm repair.References
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